KRAS and pancreatic neoplasm: Both Deltarasin and Deltazinone 1 exhibited an ‘in-cell' measured KD of ∼60 nM for PDEδ, whereas μM concentrations of the inhibitors were required to affect the proliferation of KRas-dependent pancreatic cancer cells.